血清胸苷激酶1检测对恶性肿瘤诊断及疗效评估的意义

摘要

Objective Thymidine kinase (TK1) is an enzyme involved in DNA synthesis and hence a cell eyele dependent marker. TK1 in serum ( STK1 ) in healthy controls is rather low and inereases during tumor growth. The purpose of this study was to explore the significance of STK1 as a tumor marker and its significance in the diagnosis and evaluation of treatment effect of malignancy. Methods A sensitive chemiluminescence dot-blot assay was used to measure STK1 level in 53 eases of malignant tumor patients before and after treatment, 49 cases of health-cheek persons and 18 healthy individuals as control group. Paired t-test was used for comparison of serum STK1 level in the tumor patients before and after treatment. Independent staples t-test was used for means comparison of serum STK1 level in the tumor patients before treatment as well as the tumor patients after treatment vs the health-cheek and the health control groups, re-spectively. Results The mean value of STK1 was 0.3-11.3 (2.4±2.0 ) pmol/L in tumor patients before treatment, 0.3-5.0 (0.9±0.8 ) pmol/L in tumor patients after treatment, 0.1-2.1(0.8±0.3) pmol/L in the health-eheek group and 0.5-1.2 (0.7±0.2) pmol/L in the control group. There was significantly higher STK1 level in the tumor patients before treatment as compared to the same group of patients after treatment (t=5.257, P<0.0001). There was also signifieantly higher STK1 level in the tumor patients be-fore treatment when compared with the health control group (t=3.568, P=0.001) and the health-check group (t=5.460, P<0.0001). However, there was no statistical difference of the STK1 levels between the tumor patients after treatment and the control group (t=1.056, P>0.05) and health-check group (t=0.715,P>0.05). Conclusion STK1 assay shows high sensitivity and specifieity for monitoring the effec-tiveness of tumor treatment and may be of value in predicting the risk of malignant tumor in routine health checks.%目的 探讨血清胸苷激酶1(TK1)作为肿瘤细胞增殖标志物对恶性肿瘤诊断及疗效评估的意义.方法 应用免疫印迹-增强化学发光法检测恶性肿瘤组(53例)治疗前后、体格检查组(49例)以及健康对照组(18名)的血清TK1水平.治疗前与治疗后比较用配对t检验,治疗前和后分别与健康对照组、体格检查组比较采用两独立样本均数比较t检验.结果 恶性肿瘤组治疗前STK1为0.3-11.3(2.4±2.0)pmol/L;恶性肿瘤组治疗后STK1为0.3～5.0(0.9±0.8)pmoL/L;体格检查组STKl为0.1～2.1(0.8 4-0.3)pmol/L;健康对照组STKl为0.5～1.2(0.7±0.2)pmol/L.恶性肿瘤组治疗前与治疗后之间STKl水平差异有统计学意义(t=5.257,P<0.0001).恶性肿瘤组治疗前与健康对照组和体格检查组STKl水平比较,差异均有统计学意义(t=3.568和5.460,P=0.001和<0.0001),而恶性肿瘤组治疗后与健康对照组和体格检查组STK1水平比较,差异均无统计学意义(t=1.056和0.715,P均>0.05).结论 血清TK1检测细胞增殖有较高的特异性和灵敏度,对临床监测恶性肿瘤疗效和在体格检查中进行恶性肿瘤风险筛查具有重要意义.